Trump Orders Psychedelic Drug Review for Mental Health

President Donald Trump recently signed an executive order directing the Food and Drug Administration (FDA) to expedite the review process for certain psychedelics. This directive is intended to accelerate research and approval of psychedelic-based therapies for conditions such as post-traumatic stress disorder (PTSD), depression, and addiction.

Experts express optimism, noting that patients unresponsive to existing treatments may benefit most. Studies indicate that psychedelic drugs, including psilocybin and MDMA, could offer faster and longer-lasting effects compared to traditional antidepressants like SSRIs. For instance, psilocybin-assisted treatment has shown antidepressant effects lasting at least a year in some patients.

While promising, the path to approval for some substances, like MDMA for PTSD, has faced scrutiny regarding safety and efficacy. The executive order also directs reviews for rescheduling substances that have successfully completed late-stage clinical trials. This aims to ease access for researchers studying these potentially groundbreaking treatments.

Researchers emphasize that safety and rigor must not be compromised during expedited reviews. The order seeks to facilitate research while respecting the FDA's established processes for evaluating drug safety and effectiveness. Despite the potential, experts caution against recreational use, stressing the importance of controlled environments and professional supervision.